Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics Q2 net loss widens to $3.0 million; Tome launch set Aug 25

Negative Impact 3 of 5 earnings Written later

Dermata Therapeutics reported a second-quarter 2026 net loss of $3.0 million, or $0.74 per share, up from a $1.7 million loss, or $1.66 per share, a year earlier. The filing reports no revenue, and the company said it expects its first consumer skincare product, Tome Foundational Treatment, to go on sale August 25, 2026, as it shifts from pharmaceutical development to direct-to-consumer skincare.

Key points

  • Selling, general and administrative expenses rose to $2.8 million from $1.2 million, mainly from $0.7 million of higher legal fees and $0.6 million of added marketing costs
  • Cash and cash equivalents were $4.4 million at June 30, 2026, down from $7.5 million at December 31, 2025, and the company expects cash to fund operations into the fourth quarter of 2026
  • Research and development expenses fell to $0.2 million from $0.6 million as resources shifted to the commercial launch
  • Tome Foundational Treatment is expected to launch on August 25, 2026

The filing

CompanyDermata Therapeutics, Inc. (DRMA)
Form8-K, current report
Filed with the SECAug 11, 2026, 4:06 PM ET
Accession number0001493152-26-037124

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.